Remove 2030 Remove Drug Development Remove Therapies
article thumbnail

The Long Road to End Tuberculosis

Codon

But they will need to do so if they want to meet the goals set out by the End TB Strategy , namely, to reduce TB cases by 80 percent and curb deaths by 90 percent before 2030. As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers.

Vaccine 115
article thumbnail

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger

SugarCone Biotech

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. This is an active drug development landscape with a lot of recent news. The leading program is the approved therapeutic zenocutuzumab developed by Merus N.V.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3 billion by 2030 , reflecting a compound annual growth rate (CAGR) of 6.2%.

article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. Food and Drug Administrations (FDA) diversity and inclusion in clinical trials mandate. However, it is representative of the average across most of todays trials, where only 2030% of participants are women.

article thumbnail

How organoids can redefine pre-clinical research

Drug Target Review

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. billion by 2030. 5 Organoids are recognised as New Alternative Methods (NAMs) in drug development.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease).

article thumbnail

The Race for Ozempic Alternatives: Unlocking the Future of Weight Loss Medication

DrugBank

As we step into 2024, the momentum is expected to continue, with analysts projecting the weight loss drug market to reach remarkable heights, potentially hitting $100 billion by the end of the decade. adults using obesity medications by 2030, further underlining the growing significance of this sector.